Vimarsana
Biggest News Aggregation in the World

Page 31 - Presentation Details News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Presentation Details. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Presentation Details Today - Breaking & Trending Today

Atara Biotherapeutics to Present Phase 1 Study Update of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2021 - Vimarsana News

Atara Biotherapeutics to Present Phase 1 Study Update of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2021

Press release content from Business Wire. The AP news staff was not involved in its creation.

Source: apnews.com
Slate Office REIT Reports Second Quarter 2021 Results Demonstrating Strong Leasing Activity - Vimarsana News

Slate Office REIT Reports Second Quarter 2021 Results Demonstrating Strong Leasing Activity

Press release content from Business Wire. The AP news staff was not involved in its creation. Slate Office REIT Reports Second Quarter 2021 Results Demonstrating Strong Leasing Activity July 30, 2021 GMT TORONTO--(BUSINESS WIRE)--Jul 29, 2021-- Slate Office REIT (TSX: SOT.UN) (the “REIT”), an owner and operator of North American office real estate, reported today financial results for the three and six months ended June 30, 2021. “Slate Office REIT’s strong second quarter results demonstrate the continued strengthening of the real estate market and the demand for office space,” said...

Source: apnews.com
DURECT Corporation to Present Additional Clinical Data from DUR-928 Studies in NASH (Phase 1b) and in Hepatic Impairment (Phase 1) at Upcoming International Liver Conference 2021 (EASL) - Vimarsana News

DURECT Corporation to Present Additional Clinical Data from DUR-928 Studies in NASH (Phase 1b) and in Hepatic Impairment (Phase 1) at Upcoming International Liver Conference 2021 (EASL)

Share this article Share this article CUPERTINO, Calif., June 9, 2021 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced it will present two posters at the 2021 The first poster will discuss additional efficacy signals from a Phase 1b clinical study of orally administered DUR-928 in nonalcoholic steatohepatitis (NASH) patients. Previously reported data showed that DUR-928 was well tolerated at all three doses evaluated, 50mg QD, 150mg QD, and 300mg BID (600mg/day) with overall improvement from baseline observed in liver enzymes, serum lipid profiles, liver fat by imaging, and...

Global Dementia Drugs Market Expected to Exceed $19.6 Billion In 2026 - Vimarsana News

Global Dementia Drugs Market Expected to Exceed $19.6 Billion In 2026

Global Dementia Drugs Market Expected to Exceed $19.6 Billion In 2026 - FinancialNewsMedia.com News Commentary PALM BEACH, Fla., April 20, 2021 /PRNewswire/ -- While this past year living in quarantine during the pandemic did not just create economical damage, and social disruption… it could have also increased new cases of secondary medical results from the pandemic. According to various reports the outbreak of the COVID-19 pandemic is expected to have a significant impact on the Dementia drugs market. According to a research study by Katya Numbers et al., published in Nature Reviews Neur...

BioXcel Therapeutics to Present an Update from its Ongoing Trial of BXCL701 in Aggressive Forms of Prostate Cancer at the 2021 ASCO Genitourinary Cancers Symposium - Vimarsana News

BioXcel Therapeutics to Present an Update from its Ongoing Trial of BXCL701 in Aggressive Forms of Prostate Cancer at the 2021 ASCO Genitourinary Cancers Symposium

Home / Top News / BioXcel Therapeutics to Present an Update from its Ongoing Trial of BXCL701 in Aggressive Forms of Prostate Cancer at the 2021 ASCO Genitourinary Cancers Symposium BioXcel Therapeutics to Present an Update from its Ongoing Trial of BXCL701 in Aggressive Forms of Prostate Cancer at the 2021 ASCO Genitourinary Cancers Symposium NEW HAVEN, Conn., Feb. 04, 2021 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medici...